塔西利司(GDC-032)是罗氏公司开发的一种实验性癌症药物。它是一种靶向磷脂酰肌醇3-激酶亚型PIK3CA的小分子抑制剂。

清空选项
1201657-32-0 Ethyl 2-methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanoate
BD3168421201657-32-098%
¥4000.005g常备现货
1282516-67-9 9-Bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine
BD3168741282516-67-998%
¥700.001g常备现货
1282516-66-8 5-Bromo-2-(1H-imidazol-2-yl)phenol
BD2625221282516-66-895%
¥4040.001g常备现货
1282514-63-9 9-Bromo-2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine
BD5597401282514-63-998%
¥15684.00250mg
1282516-74-8 9-Bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxylic acid
BD3168751282516-74-895+%
¥5803.001g
635702-31-7 4-Bromo-2-fluoro-N-hydroxybenzimidamide
BD263929635702-31-795%
¥886.001g
1040377-17-0 Ethyl 2-(4-bromo-1H-pyrazol-1-yl)-2-methylpropanoate
BD5568201040377-17-098%
¥4615.001g
1282513-03-4 2-(4-(2-(1-Isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanoic acid
BD6347591282513-03-498%
¥9777.00250mg
1